Journal
WORLD JOURNAL OF UROLOGY
Volume 39, Issue 9, Pages 3147-3149Publisher
SPRINGER
DOI: 10.1007/s00345-020-03416-4
Keywords
COVID-19; Urologic oncology; Clinical trial
Categories
Ask authors/readers for more resources
The COVID-19 pandemic has disrupted thousands of clinical trials globally, prompting the need for new strategies in urologic oncology. The long-term impact on this field and the understanding of unmet needs remain uncertain.
The COVID-19 pandemic has led to the suspension, termination or alteration of thousands of clinical trials as the health emergency escalated globally. Whilst the rapid suspension of certain clinical trials was necessary to ensure the safety of high-risk or vulnerable trial participants as well as healthcare workers, the long-term ramifications that this delay will have on the field of urologic oncology is unknown. The COVID-19 pandemic has highlighted the need to plan for and implement new strategies to advance our understanding of unmet areas of need in urologic oncology. The COVID-19 pandemic has led to the suspension, termination or alteration of thousands of clinical trials as the health emergency escalated globally. Whilst the rapid suspension of certain clinical trials was necessary to ensure the safety of high-risk or vulnerable trial participants as well as healthcare workers, the long-term ramifications that this delay will have on the field of urologic oncology is unknown. The COVID-19 pandemic has highlighted the need to plan for and implement new strategies to advance our understanding of unmet areas of need in urologic oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available